New drug aims to strengthen bones in kids with rare brittle bone disease
NCT ID NCT06636071
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 study tests setrusumab, a monthly IV infusion, in 6 Japanese children with osteogenesis imperfecta (types I, III, or IV), a condition that causes fragile bones and frequent fractures. The main goal is to see if the drug lowers the number of fractures, including spine fractures. All participants have had at least one fracture in the past year and have used or are using bisphosphonate therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
setrusumab (a monoclonal antibody given by IV infusion once a month)
What this could lead to
If it works, this could point toward a treatment that lowers fracture rates in children with brittle bone disease.
What could go wrong
This is a small, open-label study with only 6 participants, so results may not apply broadly. Setrusumab may not reduce fractures as hoped, and side effects from the infusion are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOGENESIS IMPERFECTA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Keio University Hospital
Tokyo, Japan
-
Osaka Metropolitan University Hospital
Osaka, Japan
-
Osaka University Hospital
Osaka, Japan